Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 2,930,000 shares, an increase of 6.5% from the November 30th total of 2,750,000 shares. Based on an average daily volume of 494,100 shares, the short-interest ratio is presently 5.9 days. Approximately 13.1% of the shares of the stock are short sold.

Agenus Trading Up 1.9 %

Shares of Agenus stock opened at $2.74 on Thursday. The firm has a market cap of $64.28 million, a PE ratio of -0.24 and a beta of 1.24. The stock has a 50 day moving average of $3.34 and a 200 day moving average of $6.21. Agenus has a 12 month low of $2.50 and a 12 month high of $19.69.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of Agenus

Several hedge funds have recently modified their holdings of AGEN. Point72 DIFC Ltd bought a new stake in Agenus in the second quarter worth $51,000. EP Wealth Advisors LLC purchased a new position in shares of Agenus in the 3rd quarter worth $55,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Agenus in the 2nd quarter worth about $106,000. HighTower Advisors LLC raised its position in shares of Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 7,530 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its position in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 9,422 shares in the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.